FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046987355> ?p ?o ?g. }

• W3046987355 endingPage "6985" @default.
• W3046987355 startingPage "6977" @default.
• W3046987355 abstract "In China, gastric cancer (GC) ranks second in incidence and mortality. Over 80% of patients with GC were diagnosed at an advanced stage with poor clinical outcome. Chemotherapy was the mainstream treatment with limited benefit. Apatinib, an inhibitor of targeting vascular endothelial growth factor receptor 2 (VEGFR2), has been approved for third-line treatment of advanced gastric cancer. However, the data of apatinib treatment in the real-world setting are limited. In this real-world study, we aimed to understand the current treatment pattern of apatinib, investigate the effectiveness and safety of apatinib in real-world settings, and explore the potential factors associated with the clinical outcomes.This was a prospective, multicenter observational study in a real-world setting. Patients aged ≥18 years with histologic diagnosis of advanced GC were eligible for enrollment. The eligible patients received either apatinib monotherapy or apatinib plus chemotherapy by physician's discretion. Apatinib treatment could be used as first-line, second-line, or third-line and above therapy. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS), ORR, DCR, and safety profile.A total of 737 patients with advanced gastric cancer treated with apatinib were included in the FAS population. A total of 54.9% patients used apatinib monotherapy and 45.1% patients used apatinib combination therapy. A total of 44.1% patients received apatinib in first-line treatment, 28.2% in second-line, and 27.7% in third-line and above. In first-line treatment, the objective response rate (ORR) was 9.09% and 16.42% in apatinib monotherapy and combination therapy groups, and disease control rate (DCR) was 78.41% and 89.29%, respectively. Patients who received combination therapy achieved significantly longer median progression-free survival (mPFS; 6.18 vs 3.52 months, p<0.01) and median overall survival (mOS; 8.72 vs 5.92 months, p<0.01) compared with monotherapy. In second-line and third-line therapy, combination therapy showed a better trend in tumor response and survival outcomes compared with monotherapy. For all patients, apatinib combined with paclitaxel were associated with longer mPFS compared with other combinations (8.88 vs 6.62 months). Multivariate analysis showed that combination with paclitaxel (p=0.02) and experience of apatinib-related specific AEs (p<0.01) were independent predictors for PFS and OS. The safety profile was tolerable and no unexpected adverse events were reported.In a real-world setting, apatinib showed a favorable effectiveness and safety profile in patients with advanced gastric cancer. Apatinib combination therapy, especially combined with paclitaxel, might lead to better survival benefit in first-line treatment. Combination with paclitaxel and the occurrence of apatinib-specific AEs were independent factors associated with better survival outcomes.NCT03333967." @default.
• W3046987355 created "2020-08-10" @default.
• W3046987355 creator A5003816728 @default.
• W3046987355 creator A5012769031 @default.
• W3046987355 creator A5019246084 @default.
• W3046987355 creator A5020172186 @default.
• W3046987355 creator A5022056759 @default.
• W3046987355 creator A5028116005 @default.
• W3046987355 creator A5028756942 @default.
• W3046987355 creator A5030513531 @default.
• W3046987355 creator A5034164330 @default.
• W3046987355 creator A5036083343 @default.
• W3046987355 creator A5041109198 @default.
• W3046987355 creator A5045264716 @default.
• W3046987355 creator A5045650596 @default.
• W3046987355 creator A5046687543 @default.
• W3046987355 creator A5055140288 @default.
• W3046987355 creator A5055503846 @default.
• W3046987355 creator A5063476565 @default.
• W3046987355 creator A5065535070 @default.
• W3046987355 creator A5067462324 @default.
• W3046987355 creator A5070903685 @default.
• W3046987355 creator A5072493954 @default.
• W3046987355 creator A5073346815 @default.
• W3046987355 creator A5073357428 @default.
• W3046987355 creator A5078093055 @default.
• W3046987355 creator A5081443241 @default.
• W3046987355 creator A5083156175 @default.
• W3046987355 creator A5084792906 @default.
• W3046987355 creator A5090524391 @default.
• W3046987355 date "2020-08-01" @default.
• W3046987355 modified "2023-10-12" @default.
• W3046987355 title "<p>Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China</p>" @default.
• W3046987355 cites W2056163905 @default.
• W3046987355 cites W2094352605 @default.
• W3046987355 cites W2102927853 @default.
• W3046987355 cites W2104759721 @default.
• W3046987355 cites W2111237964 @default.
• W3046987355 cites W2113935263 @default.
• W3046987355 cites W2122866527 @default.
• W3046987355 cites W2131972171 @default.
• W3046987355 cites W2155167083 @default.
• W3046987355 cites W2169961966 @default.
• W3046987355 cites W2219978888 @default.
• W3046987355 cites W2272984102 @default.
• W3046987355 cites W2276228008 @default.
• W3046987355 cites W2536995545 @default.
• W3046987355 cites W2553625575 @default.
• W3046987355 cites W2749020974 @default.
• W3046987355 cites W2751140959 @default.
• W3046987355 cites W2792441445 @default.
• W3046987355 cites W2794154043 @default.
• W3046987355 cites W2794271932 @default.
• W3046987355 cites W2806567377 @default.
• W3046987355 cites W2814365317 @default.
• W3046987355 cites W2889646458 @default.
• W3046987355 cites W2911435395 @default.
• W3046987355 cites W2940227720 @default.
• W3046987355 cites W91539055 @default.
• W3046987355 doi "https://doi.org/10.2147/cmar.s249153" @default.
• W3046987355 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7418160" @default.
• W3046987355 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32821164" @default.
• W3046987355 hasPublicationYear "2020" @default.
• W3046987355 type Work @default.
• W3046987355 sameAs 3046987355 @default.
• W3046987355 citedByCount "19" @default.
• W3046987355 countsByYear W30469873552020 @default.
• W3046987355 countsByYear W30469873552021 @default.
• W3046987355 countsByYear W30469873552022 @default.
• W3046987355 countsByYear W30469873552023 @default.
• W3046987355 crossrefType "journal-article" @default.
• W3046987355 hasAuthorship W3046987355A5003816728 @default.
• W3046987355 hasAuthorship W3046987355A5012769031 @default.
• W3046987355 hasAuthorship W3046987355A5019246084 @default.
• W3046987355 hasAuthorship W3046987355A5020172186 @default.
• W3046987355 hasAuthorship W3046987355A5022056759 @default.
• W3046987355 hasAuthorship W3046987355A5028116005 @default.
• W3046987355 hasAuthorship W3046987355A5028756942 @default.
• W3046987355 hasAuthorship W3046987355A5030513531 @default.
• W3046987355 hasAuthorship W3046987355A5034164330 @default.
• W3046987355 hasAuthorship W3046987355A5036083343 @default.
• W3046987355 hasAuthorship W3046987355A5041109198 @default.
• W3046987355 hasAuthorship W3046987355A5045264716 @default.
• W3046987355 hasAuthorship W3046987355A5045650596 @default.
• W3046987355 hasAuthorship W3046987355A5046687543 @default.
• W3046987355 hasAuthorship W3046987355A5055140288 @default.
• W3046987355 hasAuthorship W3046987355A5055503846 @default.
• W3046987355 hasAuthorship W3046987355A5063476565 @default.
• W3046987355 hasAuthorship W3046987355A5065535070 @default.
• W3046987355 hasAuthorship W3046987355A5067462324 @default.
• W3046987355 hasAuthorship W3046987355A5070903685 @default.
• W3046987355 hasAuthorship W3046987355A5072493954 @default.
• W3046987355 hasAuthorship W3046987355A5073346815 @default.
• W3046987355 hasAuthorship W3046987355A5073357428 @default.
• W3046987355 hasAuthorship W3046987355A5078093055 @default.
• W3046987355 hasAuthorship W3046987355A5081443241 @default.
• W3046987355 hasAuthorship W3046987355A5083156175 @default.
• W3046987355 hasAuthorship W3046987355A5084792906 @default.

• next